{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:16:05Z","timestamp":1794356165671,"version":"4.9.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"China Brain Project","award":["2021ZD0200407"],"award-info":[{"award-number":["2021ZD0200407"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12035-025-05007-z","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:27:07Z","timestamp":1747193227000},"page":"12060-12077","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cerebrospinal Fluid CCL25 as a Biomarker for Alzheimer's Disease: Associations with Pathology, Neurodegeneration, and Cognitive Decline"],"prefix":"10.1007","volume":"62","author":[{"given":"Yu-Han","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qi","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"5007_CR1","doi-asserted-by":"publisher","first-page":"101580","DOI":"10.1016\/j.eclinm.2022.101580","volume":"51","author":"A Nandi","year":"2022","unstructured":"Nandi A, Counts N, Chen S, Seligman B, Tortorice D, Vigo D et al (2022) Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine 51:101580","journal-title":"EClinicalMedicine"},{"key":"5007_CR2","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1093\/brain\/awad398","volume":"147","author":"MJ Quesnel","year":"2024","unstructured":"Quesnel MJ, Labont\u00e9 A, Picard C, Zetterberg H, Blennow K, Brinkmalm A et al (2024) Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains. Brain 147:1680\u20131695","journal-title":"Brain"},{"key":"5007_CR3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE et al (2021) Alzheimer\u2019s disease. Lancet 397:1577\u20131590","journal-title":"Lancet"},{"key":"5007_CR4","doi-asserted-by":"publisher","first-page":"e209205","DOI":"10.1212\/WNL.0000000000209205","volume":"102","author":"Y Cai","year":"2024","unstructured":"Cai Y, Shi D, Lan G, Chen L, Jiang Y, Zhou L et al (2024) Association of \u03b2-Amyloid, Microglial activation, cortical thickness, and metabolism in older adults without dementia. Neurology 102:e209205","journal-title":"Neurology"},{"key":"5007_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13024-024-00750-8","volume":"19","author":"T Guo","year":"2024","unstructured":"Guo T, Li A, Sun P, He Z, Cai Y, Lan G et al (2024) Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer\u2019s disease. Mol Neurodegener 19:58","journal-title":"Mol Neurodegener"},{"key":"5007_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179:312\u2013339","journal-title":"Cell"},{"key":"5007_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW et al (2010) Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 9:119\u2013128","journal-title":"Lancet Neurol"},{"key":"5007_CR8","doi-asserted-by":"publisher","first-page":"e75889","DOI":"10.7554\/eLife.75889","volume":"11","author":"N Lonnemann","year":"2022","unstructured":"Lonnemann N, Hosseini S, Ohm M, Geffers R, Hiller K, Dinarello CA et al (2022) IL-37 expression reduces acute and chronic neuroinflammation and rescues cognitive impairment in an Alzheimer\u2019s disease mouse model. eLife 11:e75889","journal-title":"eLife"},{"key":"5007_CR9","doi-asserted-by":"crossref","unstructured":"Heneka MT, van der Flier WM, Jessen F, Hoozemanns J, Thal RD, Boche et al (2025). Neuroinflammation in Alzheimer disease. Nat Rev Immunol 25:321\u2013352","DOI":"10.1038\/s41577-024-01104-7"},{"key":"5007_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.immuni.2012.05.008","volume":"36","author":"A Zlotnik","year":"2012","unstructured":"Zlotnik A, Yoshie O (2012) The chemokine superfamily revisited. Immunity 36:705\u2013716","journal-title":"Immunity"},{"key":"5007_CR11","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1002\/mco2.147","volume":"3","author":"H Li","year":"2022","unstructured":"Li H, Wu M, Zhao X (2022) Role of chemokine systems in cancer and inflammatory diseases. MedComm 3:e147","journal-title":"MedComm"},{"key":"5007_CR12","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3233\/JAD-210489","volume":"83","author":"A Jorda","year":"2021","unstructured":"Jorda A, Aldasoro M, Aldasoro C, Valles SL (2021) Inflammatory chemokines expression variations and their receptors in APP\/PS1 Mice. J Alzheimers Dis 83:1051\u20131060","journal-title":"J Alzheimers Dis"},{"key":"5007_CR13","doi-asserted-by":"publisher","first-page":"23496","DOI":"10.1074\/jbc.M110.117481","volume":"285","author":"J Abd Alla","year":"2010","unstructured":"Abd Alla J, Langer A, Elzahwy SS, Arman-Kalcek G, Streichert T, Quitterer U (2010) Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis *. J Biol Chem 285:23496\u201323505","journal-title":"J Biol Chem"},{"key":"5007_CR14","doi-asserted-by":"crossref","unstructured":"Huang Y, Ding H-S, Song T, Chen Y-T, Wang T, Tang Y-H et al (2021) Abrogation of CC chemokine receptor 9 ameliorates ventricular electrical remodeling in mice after myocardial infarction. Front Cardiovasc Med 8:716219","DOI":"10.3389\/fcvm.2021.716219"},{"key":"5007_CR15","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ et al (2010) Alzheimer\u2019s disease neuroimaging initiative (ADNI): clinical characterization. Neurology 74:201\u2013209","journal-title":"Neurology"},{"key":"5007_CR16","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41593-021-00886-6","volume":"24","author":"C Yang","year":"2021","unstructured":"Yang C, Farias FHG, Ibanez L, Suhy A, Sadler B, Fernandez MV et al (2021) Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci 24:1302\u20131312","journal-title":"Nat Neurosci"},{"key":"5007_CR17","doi-asserted-by":"crossref","unstructured":"Guo Y, Chen SD, You J, Huang SY, Chen YL, Zhang Y et al (2024) Multiplex cerebrospinal fluid proteomics identifies biomarkers for diagnosis and prediction of Alzheimer's disease. Nature human behaviour 8(10):2047\u20132066.","DOI":"10.1038\/s41562-024-01924-6"},{"key":"5007_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12974-022-02679-5","volume":"19","author":"ZB Wang","year":"2022","unstructured":"Wang ZB, Ma YH, Sun Y, Tan L, Wang HF, Yu JT (2022) Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-\u03b2 and tau pathology in Alzheimer\u2019s disease. J Neuroinflammation 19:316","journal-title":"J Neuroinflammation"},{"key":"5007_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-240289","volume":"100","author":"YH Chen","year":"2024","unstructured":"Chen YH, Wang ZB, Liu XP, Mao ZQ (2024) Plasma insulin predicts early amyloid-\u03b2 pathology changes in Alzheimer\u2019s disease. J Alzheimers Dis 100:321\u2013332","journal-title":"J Alzheimers Dis"},{"key":"5007_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK, Minhas DS, Lopresti BJ, Murphy A, Ward T, Koeppe RA et al (2021) Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimers Res Ther 13:99","journal-title":"Alzheimers Res Ther"},{"key":"5007_CR21","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11 Suppl 2","author":"RC Mohs","year":"1997","unstructured":"Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M et al (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. The Alzheimer\u2019s Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 Suppl 2:S13-21","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"5007_CR22","doi-asserted-by":"publisher","first-page":"112482","DOI":"10.1016\/j.exger.2024.112482","volume":"194","author":"YR Lu","year":"2024","unstructured":"Lu YR, Chang SF, Liou HH (2024) Combining the AD8 and MMSE for community-based dementia screening. Exp Gerontol 194:112482","journal-title":"Exp Gerontol"},{"key":"5007_CR23","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/psp4.12974","volume":"12","author":"S Jamalian","year":"2023","unstructured":"Jamalian S, Dolton M, Chanu P, Ramakrishnan V, Franco Y, Wildsmith K et al (2023) Modeling Alzheimer\u2019s disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB. CPT Pharmacometrics Syst Pharmacol 12:1029\u20131042","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"5007_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jalz.2015.05.010","volume":"11","author":"EE Franklin","year":"2015","unstructured":"Franklin EE, Perrin RJ, Vincent B, Baxter M, Morris JC, Cairns NJ (2015) Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer\u2019s Disease Neuroimaging Initiative 2 participants. Alzheimers Dement 11:815\u2013822","journal-title":"Alzheimers Dement"},{"key":"5007_CR25","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1002\/alz.12997","volume":"19","author":"ZB Wang","year":"2023","unstructured":"Wang ZB, Tan L, Wang HF, Chen SD, Fu Y, Gao PY et al (2023) Differences between ante mortem Alzheimer\u2019s disease biomarkers in predicting neuropathology at autopsy. Alzheimers Dement 19:3613\u20133624","journal-title":"Alzheimers Dement"},{"key":"5007_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","volume":"123","author":"TJ Montine","year":"2012","unstructured":"Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: a practical approach. Acta Neuropathol 123:1\u201311","journal-title":"Acta Neuropathol"},{"key":"5007_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS et al (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med 26:398\u2013407","journal-title":"Nat Med"},{"key":"5007_CR28","doi-asserted-by":"publisher","first-page":"369ra178","DOI":"10.1126\/scitranslmed.aag1767","volume":"8","author":"M Su\u00e1rez-Calvet","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Araque Caballero M\u00c1, Kleinberger G, Bateman RJ, Fagan AM, Morris JC et al (2016) Early changes in CSF sTREM2 in dominantly inherited Alzheimer\u2019s disease occur after amyloid deposition and neuronal injury. Sci Transl Med 8:369ra178\u2013369ra178","journal-title":"Sci Transl Med"},{"key":"5007_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P (2021) Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol 17:157\u2013172","journal-title":"Nat Rev Neurol"},{"key":"5007_CR30","doi-asserted-by":"publisher","first-page":"4386","DOI":"10.1016\/j.cell.2023.08.037","volume":"186","author":"N Sun","year":"2023","unstructured":"Sun N, Victor MB, Park YP, Xiong X, Scannail AN, Leary N et al (2023) Human microglial state dynamics in Alzheimer\u2019s disease progression. Cell 186:4386\u2013403.e29","journal-title":"Cell"},{"key":"5007_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-023-01254-1","volume":"15","author":"F Zhou","year":"2023","unstructured":"Zhou F, Sun Y, Xie X, Zhao Y (2023) Blood and CSF chemokines in Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and meta-analysis. Alzheimer\u2019s Res Ther 15:107","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"5007_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1159\/000245156","volume":"28","author":"KS Lee","year":"2009","unstructured":"Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH (2009) Peripheral cytokines and chemokines in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord 28:281\u2013287","journal-title":"Dement Geriatr Cogn Disord"},{"key":"5007_CR33","doi-asserted-by":"publisher","first-page":"5028","DOI":"10.1016\/j.cell.2022.11.019","volume":"185","author":"N Piehl","year":"2022","unstructured":"Piehl N, van Olst L, Ramakrishnan A, Teregulova V, Simonton B, Zhang Z et al (2022) Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment. Cell 185:5028\u201339.e13","journal-title":"Cell"},{"key":"5007_CR34","doi-asserted-by":"publisher","first-page":"e6197","DOI":"10.1371\/journal.pone.0006197","volume":"4","author":"T Kiyota","year":"2009","unstructured":"Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE et al (2009) CCL2 accelerates microglia-mediated A\u03b2 oligomer formation and progression of neurocognitive dysfunction. PLoS ONE 4:e6197","journal-title":"PLoS ONE"},{"key":"5007_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13195-022-01159-5","volume":"15","author":"X Li","year":"2023","unstructured":"Li X, Zhang D-F, Bi R, Tan L-W, Chen X, Xu M et al (2023) Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 15:17","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"5007_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10875-014-0032-5","volume":"34","author":"SW Pimplikar","year":"2014","unstructured":"Pimplikar SW (2014) Neuroinflammation in Alzheimer\u2019s disease: from pathogenesis to a therapeutic target. J Clin Immunol 34:64\u201369","journal-title":"J Clin Immunol"},{"key":"5007_CR37","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.3390\/ijms25073788","volume":"25","author":"A Ciechanowska","year":"2024","unstructured":"Ciechanowska A, Mika J (2024) CC Chemokine family members\u2019 modulation as a novel approach for treating central nervous system and peripheral nervous system injury\u2014a review of clinical and experimental findings. Int J Mol Sci 25:3788","journal-title":"Int J Mol Sci"},{"key":"5007_CR38","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mil\u00e0-Alom\u00e0 M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78:1471\u20131483","journal-title":"JAMA Neurol"},{"key":"5007_CR39","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/alz.12131","volume":"16","author":"M Mil\u00e0-Alom\u00e0","year":"2020","unstructured":"Mil\u00e0-Alom\u00e0 M, Salvad\u00f3 G, Gispert JD, Vilor-Tejedor N, Grau-Rivera O, Sala-Vila A et al (2020) Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer\u2019s continuum. Alzheimers Dement 16:1358\u20131371","journal-title":"Alzheimers Dement"},{"key":"5007_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256:184\u2013185","journal-title":"Science"},{"key":"5007_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608","journal-title":"EMBO Mol Med"},{"key":"5007_CR42","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL et al (2015) Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol 14:388\u2013405","journal-title":"Lancet Neurol"},{"key":"5007_CR43","doi-asserted-by":"publisher","first-page":"113045","DOI":"10.1016\/j.intimp.2024.113045","volume":"142","author":"D Xie","year":"2024","unstructured":"Xie D, Ma Y, Gao C, Pan S (2024) Piezo1 activation on microglial cells exacerbates demyelination in sepsis by influencing the CCL25\/GRP78 pathway. Int Immunopharmacol 142:113045","journal-title":"Int Immunopharmacol"},{"key":"5007_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1177\/13524585211031786","volume":"28","author":"A Bajrami","year":"2022","unstructured":"Bajrami A, Magliozzi R, Pisani AI, Pizzini FB, Crescenzo F, Marastoni D et al (2022) Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. Mult Scler J 28:550\u2013560","journal-title":"Mult Scler J"},{"key":"5007_CR45","doi-asserted-by":"publisher","first-page":"1402573","DOI":"10.3389\/fnagi.2024.1402573","volume":"16","author":"F Karimani","year":"2024","unstructured":"Karimani F, Asgari Taei A, Abolghasemi-Dehaghani MR, Safari MS, Dargahi L (2024) Impairment of entorhinal cortex network activity in Alzheimer\u2019s disease. Front Aging Neurosci 16:1402573","journal-title":"Front Aging Neurosci"},{"key":"5007_CR46","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","volume":"8","author":"MR Brier","year":"2016","unstructured":"Brier MR, Gordon B, Friedrichsen K, McCarthy J, Stern A, Christensen J et al (2016) Tau and A\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease. Sci Transl Med 8:338ra66","journal-title":"Sci Transl Med"},{"key":"5007_CR47","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3233\/JAD-230733","volume":"97","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zhao M, Yang Z, Chen L, Liu X (2024) Exploring the value of MRI measurement of hippocampal volume for predicting the occurrence and progression of Alzheimer\u2019s disease based on artificial intelligence deep learning technology and evidence-based medicine meta-analysis. J Alzheimers Dis 97:1275\u20131288","journal-title":"J Alzheimers Dis"},{"key":"5007_CR48","doi-asserted-by":"publisher","first-page":"686548","DOI":"10.3389\/fcell.2021.686548","volume":"9","author":"X Wu","year":"2021","unstructured":"Wu X, Sun M, Yang Z, Lu C, Wang Q, Wang H et al (2021) The roles of CCR9\/CCL25 in inflammation and inflammation-associated diseases. Front Cell Dev Biol 9:686548","journal-title":"Front Cell Dev Biol"},{"key":"5007_CR49","doi-asserted-by":"publisher","first-page":"154394","DOI":"10.1016\/j.metabol.2020.154394","volume":"113","author":"P Atanes","year":"2020","unstructured":"Atanes P, Lee V, Huang GC, Persaud SJ (2020) The role of the CCL25-CCR9 axis in beta-cell function: potential for therapeutic intervention in type 2 diabetes. Metabolism 113:154394","journal-title":"Metabolism"},{"key":"5007_CR50","doi-asserted-by":"crossref","unstructured":"Chen W, Johansen VBI, Legido-Quigley C (2024) Bridging brain insulin resistance to Alzheimer\u2019s pathogenesis. Trends Biochem Sci 49:939\u2013941","DOI":"10.1016\/j.tibs.2024.09.004"},{"key":"5007_CR51","doi-asserted-by":"crossref","unstructured":"Yang H-S, Yau W-YW, Carlyle BC, Trombetta BA, Zhang C, Shirzadi Z et al (2024) Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer\u2019s disease. Brain 147(6): 2158-2168","DOI":"10.1093\/brain\/awae034"},{"key":"5007_CR52","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1001\/jamaneurol.2018.1123","volume":"75","author":"JS Rabin","year":"2018","unstructured":"Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E et al (2018) Interactive associations of vascular risk and \u03b2-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol 75:1124\u20131131","journal-title":"JAMA Neurol"},{"key":"5007_CR53","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1212\/WNL.0000000000200551","volume":"99","author":"JS Rabin","year":"2022","unstructured":"Rabin JS, Pruzin J, Scott M, Yang HS, Hampton O, Hsieh S et al (2022) Association of \u03b2-amyloid and vascular risk on longitudinal patterns of brain atrophy. Neurology 99:e270\u2013e280","journal-title":"Neurology"},{"key":"5007_CR54","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ana.26460","volume":"92","author":"WW Yau","year":"2022","unstructured":"Yau WW, Shirzadi Z, Yang HS, Ikoba AP, Rabin JS, Properzi MJ et al (2022) Tau mediates synergistic influence of vascular risk and A\u03b2 on cognitive decline. Ann Neurol 92:745\u2013755","journal-title":"Ann Neurol"},{"key":"5007_CR55","doi-asserted-by":"publisher","first-page":"e208013","DOI":"10.1212\/WNL.0000000000208013","volume":"102","author":"Q Wang","year":"2024","unstructured":"Wang Q, Schindler SE, Chen G, Mckay NS, McCullough A, Flores S et al (2024) Investigating white matter neuroinflammation in Alzheimer disease using diffusion-based neuroinflammation imaging. Neurology 102:e208013","journal-title":"Neurology"},{"key":"5007_CR56","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20:5143\u20135169","journal-title":"Alzheimers Dement"},{"key":"5007_CR57","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1002\/eji.201142021","volume":"42","author":"MF Costa","year":"2012","unstructured":"Costa MF, Bornstein VU, Cand\u00e9a AL, Henriques-Pons A, Henriques MG, Penido C (2012) CCL25 induces \u03b1\u2084\u03b2\u2087 integrin-dependent migration of IL-17\u207a \u03b3\u03b4 T lymphocytes during an allergic reaction. Eur J Immunol 42:1250\u20131260","journal-title":"Eur J Immunol"},{"key":"5007_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/scrt310","volume":"4","author":"M Ullah","year":"2013","unstructured":"Ullah M, Eucker J, Sittinger M, Ringe J (2013) Mesenchymal stem cells and their chondrogenic differentiated and dedifferentiated progeny express chemokine receptor CCR9 and chemotactically migrate toward CCL25 or serum. Stem Cell Res Ther 4:99","journal-title":"Stem Cell Res Ther"},{"key":"5007_CR59","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/eji.201242545","volume":"42","author":"B Silva-Santos","year":"2012","unstructured":"Silva-Santos B (2012) Driving IL-17\u207a \u03b3\u03b4 T-cell migration in allergic reactions: a new \u201cinflammatory\u201d role for the \u201chomeostatic\u201d chemokine CCL25. Eur J Immunol 42:1097\u20131101","journal-title":"Eur J Immunol"},{"key":"5007_CR60","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11011-019-00512-2","volume":"35","author":"SA Ferguson","year":"2020","unstructured":"Ferguson SA, Varma V, Sloper D, Panos JJ, Sarkar S (2020) Increased inflammation in BA21 brain tissue from African Americans with Alzheimer\u2019s disease. Metab Brain Dis 35:121\u2013133","journal-title":"Metab Brain Dis"},{"key":"5007_CR61","doi-asserted-by":"crossref","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J et al (2023) A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nature Aging 3(9):1079\u20131090.","DOI":"10.1038\/s43587-023-00471-5"},{"key":"5007_CR62","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13195-024-01521-9","volume":"16","author":"MD Howe","year":"2024","unstructured":"Howe MD, Britton KJ, Joyce HE, Menard W, Emrani S, Kunicki ZJ et al (2024) Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer\u2019s disease. Alzheimers Res Ther 16:154","journal-title":"Alzheimers Res Ther"},{"key":"5007_CR63","doi-asserted-by":"crossref","unstructured":"Zhang D, Zhang W, Ming C, Gao X, Yuan H, Lin X et al (2024) P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy. Neuron 112(10):1676\u20131693","DOI":"10.1016\/j.neuron.2024.02.017"},{"key":"5007_CR64","doi-asserted-by":"crossref","unstructured":"Jarek DJ, Mizerka H, Nuszkiewicz J, Szewczyk-Golec K (2024) Evaluating p-tau217 and p-tau231 as biomarkers for early diagnosis and differentiation of Alzheimer's disease: a narrative review. Biomedicines 12(4):786","DOI":"10.3390\/biomedicines12040786"},{"key":"5007_CR65","doi-asserted-by":"crossref","unstructured":"Sano T, Ochiai T, Nagayama T, Nakamura A, Kubota N, Kadowaki T et al (2023) Genetic reduction of insulin signaling mitigates amyloid-\u03b2 deposition by promoting expression of extracellular matrix proteins in the brain. Journal of Neuroscience 43(43):7226\u20137241","DOI":"10.1523\/JNEUROSCI.0071-23.2023"},{"key":"5007_CR66","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, Janelidze S, Li Y, He Y et al (2023) CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med 29:1954\u20131963","journal-title":"Nat Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05007-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05007-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05007-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:38:30Z","timestamp":1757173110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05007-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":66,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["5007"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05007-z","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"28 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all ADNI participants, and ADNI received approval from the institutional review boards at all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}